CD62L expression in chronic lymphocytic leukemia patients

Background: Chronic lymphocytic leukemia is the most common adult leukemia and often presents as early-stage disease. It could be stable for many years with no or minimal intervention. CD62L is a one of the selectin family of adhesion molecules which plays an important role in the trafficking/homing of lymphocytes to the lymph node. The objective of this study was to evaluate CD62L expression in chronic lymphocytic leukemia, and its effect on survival of malignant B-cells. Methods: This study was conducted on 35 patients of chronic lymphocytic leukemia and 15 age & sex matched healthy individuals as a control group. All patients were subjected to full history taking, clinical examination and laboratory investigations. CD62L/CD19 expression on lymphocytes was measured for all the study subjects using Flowcytometry technique before and after cell culture. Results: CD62L/CD19 expression increased minimally in control subjects at day 7 compared to day 0 (The mean ±SD 33.9±5.3 and 18.03±3.4 respectively) (P-Value < 0.001), while the diseased group showed marked elevation at day 7 than day 0 (The mean ±SD 90.7±6.4 and 36.9±17.2 respectively) (P-Value < 0.001). CD62L/CD19 expression in patients were higher than the control subjects at day 0 (The mean ±SD 36.9±17.2 and 18.03±3.4 respectively) and about three folds increase at day 7 (the mean ±SD 90.7±6.4 and 33.9±5.3 respectively) (P- Value < 0.001). Conclusions: There is high expression of CD62L on lymphocytic cells in chronic lymphocytic leukemia patients associated with increased survival of malignant B-cells. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.